New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs Thymosin Alpha-1

Chonluten vs Thymosin Alpha-1

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
2–3 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.8–1.6 mg
Frequency
Daily for 10–30 days
Twice weekly
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Enhances T-cell and NK cell activity
  • Supports recovery from viral and bacterial infections
  • May reduce inflammation systemically
  • Supports healthy aging and immune resilience
  • Improves vaccine response
  • Supports liver health
  • May help with chronic fatigue syndrome and post-viral conditions
  • Approved in multiple countries for hepatitis B and C treatment
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Injection site irritation
  • Mild flu-like symptoms initially (immune activation)
  • Fatigue (rare)
Stacks With